on Eckert & Ziegler Strahlen- Und Medizintechnik AG (isin : DE0005659700)
Eckert & Ziegler Signs Manufacturing Agreement with Pentixapharm
On April 24, 2025, Eckert & Ziegler Radiopharma GmbH, a subsidiary of Eckert & Ziegler SE, announced a manufacturing agreement with Pentixapharm. This deal entails the production and distribution of Y90-PentixaTher, a CXCR4-targeting radiotherapeutic, for clinical trials. This compound targets cancer cells with CXCR4 overexpression, prevalent in certain hematologic and solid tumors.
The agreement stipulates that Eckert & Ziegler will manage doses under GMP conditions for trial sites. However, this contract is limited to clinical development, allowing Pentixapharm strategic freedom for future developments. According to Dr. Harald Hasselmann, CEO of Eckert & Ziegler SE, this collaboration supports innovative cancer therapy progress. Dr. Dirk Pleimes, CEO of Pentixapharm, highlighted the importance of reliable production for their clinical supply chain.
R. H.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Eckert & Ziegler Strahlen- Und Medizintechnik AG news